BioVie, Inc. Common Stock
BIVIStock
$1.72−76.13%52W
Market Cap$13.35M
P/E—
Div yield—
Beta0.70
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)4.99%
Price vs S&P 500 (4W)-4.42%
VGM Score39.05
Market Capitalization$13.35M
Earnings Surprise History
Q3 26-0.70est. -0.74
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BIVIBioVie, Inc. Common Stock | — | — | D | $1.72 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
BioVie Inc. is a clinical-stage biopharmaceutical company developing therapies for neurological and liver diseases. Its lead program, NE3107, is advancing through Phase 3 clinical trials for mild to moderate Alzheimer's disease. BIV201 targets life-threatening complications of advanced liver disease, including cirrhosis from hepatitis, non-alcoholic fatty liver disease, and alcohol-related liver injury.